NEW YORK (Reuters Health) – There’s no evidencethat using the allergy/asthma drug Singulair increases the risk ofdepression or suicide, according to a review of data from threeclinical trials.

Recent reports have raised concerns of a link between suicideand Singulair, also known by the generic name montelukast. Thecurrent study, conducted by Dr. Janet Holbrook and Dr. RaidaHarik-Khan from the American Lung Association, indicates that theconcerns are not warranted.

A total of 1352 patients were enrolled in the clinical trials,and 536 were treated with montelukast. All of the trials wereconducted by the American Lung Association’s Asthma ClinicalResearch Centers (ACRC).

social poster